The recent GlaxoSmithKline and Pfizer consumer joint venture intends to sell off £1 billion worth of assets to raise some cash for operations and is losing no time in doing so. A plant in Canada with 400 employees is now on the front line of that effort while giving a Taiwan-based CDMO a North American manufacturing foothold.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,